The role of antibiotics in Crohn's disease

Digestive Diseases

Volumn 17, Issue 1, 1999, Pages 1-5

  Cangemi, J R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibiotics; Atypical mycobacteria; Crohn's disease; Fecal stream; Intestinal permeability

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CEFALOTIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PLACEBO; RIFABUTIN; RIFAMPICIN; STEROID; TETRACYCLINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; FECES; HISTOLOGY; HISTOPATHOLOGY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; CROHN DISEASE; FECES; HUMANS; INTESTINAL MUCOSA; INTESTINES;

EID: 0032811419     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016897     Document Type: Review

References (49)

1. Sankey EA, Dhillon AP, Anthony A, Wakefield AJ, Sim R, More L, Hudson M, Sawyerr AM, Pounder RE: Early mucosal changes in Crohn's disease. Gut 1993;34:375-381.
2. Wyatt J, Oberhuber G, Pongratz S, Puspok A, Moser G, Novacek G, Lochs H, Vogelsang H: Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997;92:1891-1896.
3. Peeters M, Ghoos Y, Maes B, Heile M, Geboes K, Vantrappen G, Rutgeerts P: Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 1994;39: 2170-2176.
4. Katz KD, Hollander SD, Vadheim CM, McIlree C, Delahunty T, Dadufalza VD, Krugliak P, Motter JI: Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989;97:927-931.
5. Hilsden RJ, Meddings JB, Sutherland LR: Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110: 1395-1403.
6. Wyatt J, Vogelsgang H, Hubl W, Waldhoer T, Lochs H: Intestinal permeability and prediction of relapse in Crohn's disease. Lancet 1993;341: 1437-1439.
7. + B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995;108:132-137.
8. Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, Baert F, Vermeire S, Vlietinck R, Rutgeerts P: Clustering of increased small intestine permeability in families with Crohn's disease. Gastroenterology 1997;113: 802-807.
9. Darchis I, Colombel JF, Cortot A, Devred M, Paris JC: Crohn's disease in a married couple and their four children. Lancet 1989;i:737.
10. Cave DR, Freedman LS: Seasonal variations in the clinical presentation of Crohn's disease and ulcerative colitis. Int J Epidemiol 1975;4:317.
11. Cartun RW, Van Kruiningen HJ, Pedersen CA, Berman NM: An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993;6:212-219.
12. Ambrose NS, Johnson M, Burdon DW, Keighley MRB: Incidence of pathogenic bacterial from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 1984; 71:623-625.
13. Keighley MRB: Infection and the use of antibiotics in Crohn's disease. Can J Surg 1984;27: 438-441.
14. Van De Merwe JP, Shroder AM, Wensinck F, Hazenbrag MP: The obligate anaerobic fecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988;23:1125-1131.
15. Giaffer MH, Holdsworth CD, Duerden BI: Virulence properties of E. coli strains isolated from patients with inflammatory bowel disease. Gut 1992;33:646-650.
16. Pavli P, Gibson PR: Pathogenic factors in inflammatory bowel disease. Dig Dis 1992;10:72-84.
17. Sartor RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.
18. Sartor RB: Antimicrobial therapy of inflammatory bowel disease: Implications for pathogenesis and management. Can J Gastroenterol 1993;7:132-138.
19. Sartor RB: Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990;4:271-277.
20. Chadwick VS, Anderson RP: Microorganisms and Their Products in Inflammatory Bowel Disease. Inflammatory Bowel Disease, New York, Elsevier, 1992, pp 241-258.
21. Klasen IS, Melief MJ, van Halteren AGS, Schouten WR, van Blankenstein M, Hoke G, de Vissier H, Hooijkaas H, Hazenberg MP: The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease. Clin Immunol Immunopathol 1994;71:303-308.
22. Issacs KL, Sartor RB, Haskill S: Cytokine messener RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1997; 103:1587-1595.
23. Harper PH, Lee ECG, Kettlewell MGW, Bennett MK, Jewell DP: Role of fecal stream in the maintenance of Crohn's colitis. Gut 1985;26: 279-284.
24. Janowitz HJ, Crowen EC, Sachar DB: The role of the fecal stream in Crohn's disease: A historical and analytic review. Inflamm Bowel Dis 1998;4:29-39.
25. Rutgeerts P, Goboes K, Peeters M, Heile M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-774.
26. Cameron JL, Hamilton SR, Coleman J, Sitzmann JV, Bayless TM: Patterns of ileal recurrence in Crohn's disease: A prospective randomized study. Ann Surg 1992;215:546-552.
27. Hanauer SB: Drug therapy: Inflammatory bowel disease. N Engl J Med 1996;334:841-848.
28. Peppercorn MA: Antibiotics are effective therapy for Crohn's disease. Inflamm Bowel Dis 1997;3:318-319.
29. Pallone F, Boirivant M, Fais S, Luzza F, Doldo P. Monteleone G, Aloi A: Antibacterial drugs in Crohn's disease. Ital J Gastroenterol 1992; 24(suppl 2):17-18.
30. Spirit MJ: Antibiotics in inflammatory bowel disease: New choices for an old disease. Am J Gastroenterol 1994;89:974-978.
31. Van Kruiningen HJ: On the use of antibiotics in Crohn's disease. J Clin Gastroenterol 1995; 20:310-316.
32. Gitnick G: Antibiotics and inflammatory bowel disease. Gastroenterol Clin Noth Am 1989;18: 51-56.
33. Hudson MJ, Hill MJ, Elliott PR, Berghouse LM, Burnham WR, Lennard-Jones JE: The microbial flora of the rectal mucosa and feces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 1984;18:335-345.
34. Danzi JT: Trimethoprim-sulfamethoxazole therapy of inflammatory bowel disease. Gastroenterology 1989;96:A110.
35. Moss AA, Carbone JV, Krsessel HY: Radiologie and clinical assessment of broad spectrum antibiotic therapy in Crohn's disease. AJR 1978; 131:787-790.
36. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, Levine J, Thomson A, Alpert E, Prokipchuk E: Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075.
37. Rutgeerts P, Heile M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
38. Prantera C, Zannoni F, Seribano ML, Berto E, Andrieoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn's disease: A randomized controlled clinical trial of metronidazole plus ciprofloxicin. Am J Gastroenterol 1996;91:328-332.
39. Prantera C, Kohn A, Zannoni F, Spimpolo N, Bonfa M: Metronidazole plus ciprofloxicin in the treatment of active refractory Crohn's disease: Results of an open study. J Clin Gastroenterol 1994;19:79-88.
40. Greenbloom SL, Steinhart AH, Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's desease. Can J Gastroenterol 1998;12:53-56.
41. Peppercorn MA: Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-237.
42. Colombel JF, Lemann M, Cassagnon M, et al: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology 1997;112:A951.
43. Saverymuttu S, Hodgson HJF, Chadwick VS: Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut 1985;26: 994-998.
44. Clarkston WK, Presti ME, Petersen PF, Zachary PE, Fan WX, Leonardi CL, Vernava AM, Longo WE, Kreeger JM: Role of Mycobacterium paratuberculosis in Crohn's disease: A prospective, controlled study using polymerase chain reaction. Dis Colon Rectum 1998;41:195-199.
45. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J,. Wilkinson S, Rhodes P, Roberts G, Lawrie BW, Evans KT, Jenkins PA, Williams GT, Strohmeyer G, Kreuzpaintner G, Thomas GAO, Calcraft B, Davies PS, Morris TJ, Morris J: Controlled trial of anti-tuberculosis chemotherapy for two years in Crohn's disease. Gut 1995;35:363-368.
46. Rutgeerts P, Geboes K, Vantrappen G, Van Isveldt J, Peeters M, Penninckx F, Heile M: Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol 1992;15:24-28.
47. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: Results of a controlled double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-518.
48. Borody TJ, Pearce L, Bampton TA, et al: Treatment of severe Crohn's disease using rifabutin-macrolide-clofazimine combination: Interim report. Gastroenterology 1998;114:A938.
49. Feagan B: Antibiotics are not effective therapy for Crohn's disease (time to remove the rose-colored glasses). Inflamm Bowel Dis 1997;3: 314-317.